Jazz Pharmaceuticals Inc.
"We have three other assets in various stages of development, but until we are fully reinstated with our note-holders, and probably until we get profitable, the development for those programs is currently on hold," Quinn said. The three halted candidates were in development as treatments for epilepsy and bipolar disorder; to treat restless legs syndrome; and as a treatment for epilepsy in patients who continue to have seizures while on stable anti-epileptic regimens. Jazz shares closed the week up 39 cents, or 11%, at $3.88.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CORPORATE; drug development|
|Article Type:||Brief article|
|Date:||Jun 29, 2009|
|Previous Article:||Osiris Therapeutics Inc.|
|Next Article:||Merck & Co. (Whitehouse Station NJ) sold $4.25 billion debt in four parts last week, according to a market source familiar with the sale.|